丹参酮ⅡA磺酸钠辅助治疗冠心病的疗效观察

Observation of efficacy of sodium tanshinoneⅡA sulfonate in adjuvant treatment of coronary artery disease

目的评价丹参酮ⅡA磺酸钠辅助治疗冠心病的临床效果。方法110例冠心病患者,采取随机数字表法分为对照组和观察组,各55例。对照组患者采用阿托伐他汀钙片治疗,观察组患者在对照组基础上配合丹参酮ⅡA磺酸钠治疗。比较两组患者临床疗效及血脂指标、炎症因子水平。结果观察组治疗总有效率96.36%明显高于对照组的80.00%,差异有统计学意义(P<0.05)。治疗前,两组甘油三脂(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、脂联素(APN)及肿瘤坏死因子-α(TNF-α)、超敏C反应蛋白(hs-CRP)水平比较,差异无统计学意义(P>0.05);治疗后,两组TG、TC、LDL-C、HDL-C、APN及TNF-α、hs-CRP水平均优于治疗前,且观察组TG(1.35±0.28)mmol/L、TC(4.55±0.50)mmol/L、LDL-C(2.15±0.48)mmol/L、HDL-C(1.48±0.30)mmol/L、APN(6.28±0.70)mg/L及TNF-α(35.55±3.45)ng/L、hs-CRP(4.45±0.47)mg/L均优于对照组的(1.76±0.30)mmol/L、(5.40±0.55)mmol/L、(2.76±0.53)mmol/L、(1.35±0.25)mmol/L、(5.35±0.65)mg/L、(45.50±3.55)ng/L、(5.76±0.52)mg/L,差异有统计学意义(P<0.05)。结论丹参酮ⅡA磺酸钠辅助治疗冠心病,可有效促进患者血脂、炎症因子水平改善,提高治疗效果,患者预后状况良好。

Objective To evaluate the clinical effect of sodium tanshinoneⅡA sulfonate in adjuvant treatment of coronary artery disease.Methods A total of 110 patients with coronary heart disease were divided into control group and observation group by random numerical table,with 55 cases in each group.Patients in the control group were treated with atorvastatin calcium tablets,and patients in the observation group were treated with sodium tanshinoneⅡA sulfonate on the basis of the control group.The clinical efficacy,blood lipid indexes and inflammatory factor levels were compared between the two groups.Results The total effective rate 96.36%of the observation group was significantly higher than 80.00%of the control group,and the difference was statistically significant(P<0.05).Before treatment,there were no statistically significant differences in triglyceride(TG),total cholesterol(TC),low-density lipoprotein-cholesterol(LDL-C),high-density lipoprotein-cholesterol(HDL-C),adiponectin(APN)and tumor necrosis factor-α(TNF-α)and high-sensitivity C-reactive protein(hs-CRP)levels between the two groups(P>0.05).After treatment,the levels of TG,TC,LDL-C,HDL-C,APN,TNF-α,and hs-CRP in the two groups were better than those before treatment;TG(1.35±0.28)mmol/L,TC(4.55±0.50)mmol/L,LDL-C(2.15±0.48)mmol/L,HDL-C(1.48±0.30)mmol/L,APN(6.28±0.70)mg/L,TNF-α(35.55±3.45)ng/L and hs-CRP(4.45±0.47)mg/L of the observation group were better than(1.76±0.30)mmol/L,(5.40±0.55)mmol/L,(2.76±0.53)mmol/L,(1.35±0.25)mmol/L,(5.35±0.65)mg/L,(45.50±3.55)ng/L,(5.76±0.52)mg/L of the control group;all the differences were statistically significant(P<0.05).Conclusion The adjuvant treatment of sodium tanshinoneⅡA sulfonate can effectively improve the blood lipids and inflammatory factors of patients with coronary heart disease,improve their therapeutic effect with good prognosis.